Join
Live feed
·
PRReleasevia Quantisnow
Perspective Therapeutics Inc. logo

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

ByQuantisnow·Wall Street's wire, on your screen.
CATX· Perspective Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CATX (Perspective Therapeutics Inc.) and more on Quantisnow.